Dataset Information

{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

ABSTRACT: Pancreatic cancers generally respond poorly to chemotherapy, prompting a need to identify agents that could sensitize tumors to treatment. In this study, we investigated the response of human pancreatic cells to γ-tocotrienol (γ-T3), a novel, unsaturated form of vitamin E found in palm oil and rice bran oil, to determine whether it could potentiate the effects of gemcitabine, a standard of care in clinical treatment of pancreatic cancer. γ-T3 inhibited the in vitro proliferation of pancreatic cancer cell lines with variable p53 status and potentiated gemcitabine-induced apoptosis. These effects correlated with an inhibition of NF-κB activation by γ-T3 and a suppression of key cellular regulators including cyclin D1, c-Myc, cyclooxygenase-2 (COX-2), Bcl-2, cellular inhibitor of apoptosis protein, survivin, vascular endothelial growth factor (VEGF), ICAM-1, and CXCR4. In an orthotopic nude mouse model of human pancreatic cancer, p.o. administration of γ-T3 inhibited tumor growth and enhanced the antitumor properties of gemcitabine. Immunohistochemical analysis indicated a correlation between tumor growth inhibition and reduced expression of Ki-67, COX-2, matrix metalloproteinase-9 (MMP-9), NF-κB p65, and VEGF in the tissue. Combination treatment also downregulated NF-κB activity along with the NF-κB-regulated gene products, such as cyclin D1, c-Myc, VEGF, MMP-9, and CXCR4. Consistent with an enhancement of tumor apoptosis, caspase activation was observed in tumor tissues. Overall, our findings suggest that γ-T3 can inhibit the growth of human pancreatic tumors and sensitize them to gemcitabine by suppressing NF-κB-mediated inflammatory pathways linked to tumorigenesis.

SUBMITTER: Kunnumakkara AB

PROVIDER: S-EPMC2970705 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Kunnumakkara Ajaikumar B AB Sung Bokyung B Ravindran Jayaraj J Diagaradjane Parmeswaran P Deorukhkar Amit A Dey Sanjit S Koca Cemile C Yadav Vivek R VR Tong Zhimin Z Gelovani Juri G JG Guha Sushovan S Krishnan Sunil S Aggarwal Bharat B BB

Cancer research 20100923 21

Pancreatic cancers generally respond poorly to chemotherapy, prompting a need to identify agents that could sensitize tumors to treatment. In this study, we investigated the response of human pancreatic cells to γ-tocotrienol (γ-T3), a novel, unsaturated form of vitamin E found in palm oil and rice bran oil, to determine whether it could potentiate the effects of gemcitabine, a standard of care in clinical treatment of pancreatic cancer. γ-T3 inhibited the in vitro proliferation of pancreatic ca ...[more]

PMID: 20864511

Similar Datasets

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death with a median survival time of 6-12 months. Most patients present with disseminated disease and the majority are offered palliative chemotherapy. With no approved treatment modalities for patients who progress on chemotherapy, we explored the effects of long-term gemcitabine administration on the tumor microenvironment to identify potential therapeutic options for chemorefractory PDAC. Using a combination of mouse models, primary cell line-derived xenografts, and established tumor cell lines, we first evaluated chemotherapy-induced alterations in the tumor secretome and immune surface proteins by high throughput proteomic arrays. In addition to enhancing antigen presentation and immune checkpoint expression, gemcitabine consistently increased the synthesis of CCL/CXCL chemokines and TGFβ-associated signals. These secreted factors altered the composition of the tumor stroma, conferring gemcitabine resistance to cancer-associated fibroblasts in vitro and further enhancing TGFβ1 biosynthesis. Combined gemcitabine and anti-PD-1 treatment in transgenic models of murine PDAC failed to alter disease course unless mice also underwent genetic or pharmacologic ablation of TGFβ signaling. In the setting of TGFβ signaling deficiency, gemcitabine and anti-PD-1 led to a robust CD8+ T-cell response and decrease in tumor burden, markedly enhancing overall survival. These results suggest that gemcitabine successfully primes PDAC tumors for immune checkpoint inhibition by enhancing antigen presentation only following disruption of the immunosuppressive cytokine barrier. Given the current lack of third-line treatment options, this approach warrants consideration in the clinical management of gemcitabine-refractory PDAC. SIGNIFICANCE: These data suggest that long-term treatment with gemcitabine leads to extensive reprogramming of the pancreatic tumor microenvironment and that patients who progress on gemcitabine-based regimens may benefit from multidrug immunotherapy.See related commentary by Carpenter et al., p. 3070 GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/15/3101/F1.large.jpg.

Project description:Mitogen activated protein kinase kinase kinase 1 (MAP3K1), is involved in various cancer signaling networks including the NF-B, JNK, ERK, and p38 pathways. Functioning as a signaling kinase in these oncogenic pathways, MAP3K1 contributes to tumor growth and metastasis. Additionally, higher transcript levels of MAP3K1 in pancreatic patient tumors is associated with poorer 5-year survival, suggesting MAP3K1 is an attractive therapeutic target. Activation of inhibitor of nuclear factor NF-κB kinase subunit-β (IKK), an important phosphorylation target of MAP3K1, was shown to be important in pancreatic cancer (PC) disease onset and progression. We previously reported a quinoxaline analog, Analog 84, which inhibits IKK phosphorylation and downstream NF-B pathway activation. To improve the metabolic stability and bioavailability of Analog 84, we developed 51-106, which moved -F atom to block a site of potential metabolism. Using a chemoproteomics approach for kinome profiling, KiNativTM, we show 51-106 selectively binds to MAP3K1 in an ATP-competitive manner. Follow up studies show 51-106 inhibits downstream phosphorylation of IKK and blocks TNF-induced MAP3K1-IKK-mediated NF-B activity. Treatment of PC cell lines MiaPaCa2 and PANC-1 with 51-106 inhibits cell growth and migration with low micromolar potency. Utilizing 51-106 as a tool to study MAP3K1 signaling, we use phosphoproteomics analysis to show MAP3K1 inhibition leads to a dose dependent decrease in NPM1 T199 phosphorylation, suggesting NPM1 may play a role in MAP3K1 signaling. We observe a dose-dependent S-phase arrest in cells treated with 51-106, potentially linking MAP3K1 inhibition to a dysfunctional DNA damage response. Consistent with this observation, in combination studies, 51-106 synergistically inhibited growth with gemcitabine in LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre (KPC) cell lines in vitro and in KPC syngeneic orthotopic implantation mouse model of pancreatic cancer in vivo. Our data indicated that MAP3K1 inhibition may represent a promising therapeutic in PC. These findings underscore the need for further investigation into the molecular interactions and downstream effects of the MAP3K1-NPM1 signaling axis.

Dataset Information

{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Publications

{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets